Brain+ ApS (BRAINP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Brain+ ApS (BRAINP) has a cash flow conversion efficiency ratio of -0.964x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-13.93 Million ≈ $-2.18 Million USD) by net assets (Dkr14.45 Million ≈ $2.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BRAINP company net worth for the company's overall valuation and market capitalisation.
Brain+ ApS - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Brain+ ApS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Brain+ ApS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Brain+ ApS ranked by their cash flow conversion efficiency. See BRAINP operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
REVITALIST L.A.W. LTD
F:4DO
|
N/A |
|
National World PLC
LSE:NWOR
|
0.024x |
|
Norrland Gold Corp
V:NORR
|
-0.074x |
|
DP Poland Plc
LSE:DPP
|
0.072x |
|
James Cropper PLC
LSE:CRPR
|
0.161x |
|
Vivanco Gruppe AG
F:VG0K
|
0.164x |
|
Shanti Overseas (India) Limited
NSE:SHANTI
|
-0.015x |
|
ALGERNON PHARMACEUT. A
F:AGW0
|
N/A |
Annual Cash Flow Conversion Efficiency for Brain+ ApS (2017–2024)
The table below shows the annual cash flow conversion efficiency of Brain+ ApS from 2017 to 2024. View Brain+ ApS (BRAINP) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Dkr10.98 Million ≈ $1.72 Million |
Dkr-9.25 Million ≈ $-1.45 Million |
-0.842x | +23.90% |
| 2023-12-31 | Dkr12.38 Million ≈ $1.94 Million |
Dkr-13.71 Million ≈ $-2.14 Million |
-1.107x | -350.45% |
| 2022-12-31 | Dkr16.38 Million ≈ $2.56 Million |
Dkr-4.03 Million ≈ $-629.80K |
-0.246x | +39.61% |
| 2021-12-31 | Dkr20.60 Million ≈ $3.22 Million |
Dkr-8.38 Million ≈ $-1.31 Million |
-0.407x | -110.70% |
| 2020-12-31 | Dkr1.92 Million ≈ $300.09K |
Dkr7.29 Million ≈ $1.14 Million |
3.801x | +74401.98% |
| 2019-12-31 | Dkr3.20 Million ≈ $500.19K |
Dkr16.31K ≈ $2.55K |
0.005x | -99.56% |
| 2018-12-31 | Dkr6.24 Million ≈ $975.54K |
Dkr7.29 Million ≈ $1.14 Million |
1.169x | +7.41% |
| 2017-12-31 | Dkr6.70 Million ≈ $1.05 Million |
Dkr7.29 Million ≈ $1.14 Million |
1.089x | -- |
About Brain+ ApS
Brain+ A/S, a healthtech company, develops and commercializes technology solutions in dementia care primarily for cognitive stimulation therapy. The company is developing Ayla, a scalable dementia care platform that offers practical, human-centered, and clinically proven software-based dementia therapy and care solutions. It is also developing Ayla " your CST Assistant, a software-based dementia … Read more